| |
| Xpention
Genetics, Inc. is
a biotechnology company that was formed to develop both immunological
and molecular tests for cancer detection in animals and humans
as well as therapeutic vaccines and other treatment methods
for both veterinary and human cancers. Xpention through its
subsidiary has licensed, exclusive rights to a specific genetic
marker called the p65 that has highly specific correlation
to numerous cancers. |
| |
 |
|
|
|
|
| |
| |
|
|
| |
| Bayview
Corporation Effects Name Change and Forward Split |
| |
04/13/05 : Xpention Genetics
Inc. (OTC BB: XPNG), formerly Bayview Corporation (OTC BB: BYVW),
completes name change and thirteen for one forward
split. The name change
and stock split was effective Tuesday, April 12, 2005.
The name change reflects the Company's acquisition of Xpention, Inc. and the
change of business. Xpention, Inc. is a biotechnology company that was formed
to develop both immunological and molecular tests for cancer detection in animals
and humans as well as therapeutic vaccines and other treatment methods for both
animal and human cancers.
David Kittrell, CEO, commented, "We are extremely excited to enter the public
market. I believe shareholders will benefit greatly from our business combination
which will trade on the Over-The-Counter Bulletin Board as Xpention Genetics,
Inc."
"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements
as defined in the Private Securities Litigation Reform Act of 1995. Such statements
are subject to numerous risks and uncertainties. Actual results may vary significantly
from the results expressed or implied in such statements. Factors that could
cause actual results to materially differ from forward-looking statements include,
but are not limited to, the Company's ability to meet the terms and conditions
required to obtain its project financing, risks and delays associated with product
development, risk of market acceptance of new products, risk of technology or
product obsolescence, competitive risks, reliance on development partners and
the need for additional capital.. |
|
